Invention Grant
- Patent Title: Anti-angiopoietin-2 antibodies that induce Tie2 activation
-
Application No.: US16995707Application Date: 2020-08-17
-
Publication No.: US11498962B2Publication Date: 2022-11-15
- Inventor: Gou Young Koh , Jeomil Bae , Mi Jeong Kim , Jin-Sung Park , Su Jin Seo , Jaeryung Kim , Jang Ryul Park , Pilhan Kim , Wangyuhl Oh
- Applicant: INSTITUTE FOR BASIC SCIENCE , KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
- Applicant Address: KR Daejeon; KR Daejeon
- Assignee: INSTITUTE FOR BASIC SCIENCE,KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
- Current Assignee: INSTITUTE FOR BASIC SCIENCE,KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
- Current Assignee Address: KR Daejeon; KR Daejeon
- Agency: McNeill Baur PLLC
- Priority: KR10-2019-0018769 20190218
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/22 ; A61P35/00 ; A61K45/06 ; A61K39/00

Abstract:
The present invention relates to mouse antibodies that bind to angiopoietin-2 (Ang2), humanized anti-Ang2 antibodies derived therefrom, and the use thereof. The anti-Ang2 antibodies have a dual function of activating the Tie2 receptor together with neutralizing Ang2. The anti-Ang2 antibodies show the property of normalizing abnormal and pathological blood vessels, and thus exhibits therapeutic efficacy against various diseases and disorders associated with abnormal blood vessels. The present invention further provides an angiogenesis inhibitor and a composition for treatment of diseases associated with abnormal Ang2 expression and Tie2 dysregulation, which comprise the antibody as an active ingredient, and a composition for diagnosing diseases associated with Ang2 inhibition and Tie2 activation, which comprises the antibody.
Public/Granted literature
- US20210079083A1 Anti-Angiopoietin-2 Antibodies and Uses Thereof Public/Granted day:2021-03-18
Information query